Published in Eur J Clin Pharmacol on July 01, 1999
The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol (2011) 1.28
Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br J Clin Pharmacol (2010) 0.89
Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur J Clin Pharmacol (2003) 0.89
Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4? Br J Clin Pharmacol (2002) 0.84
Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J (2007) 0.83
Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. J Clin Pharmacol (2015) 0.81
Influence of a Nigerian honey on CYP3A4 biotransformation of quinine in healthy volunteers. J Clin Pharm Ther (2015) 0.75
Subcutaneous fluid administration in elderly subjects: validation of an under-used technique. J Am Geriatr Soc (1991) 1.49
Influence of thyroid hormones on the responses of smooth muscle to drugs. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 1.45
Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob Agents Chemother (2003) 1.34
The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. Eur J Clin Pharmacol (1982) 1.29
Protein binding of some non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Clin Pharmacokinet (1982) 1.19
Determination of aspirin and its major metabolites in plasma by high-performance liquid chromatography without solvent extraction. J Chromatogr (1981) 1.08
Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci (2001) 1.06
Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine. Br J Clin Pharmacol (1997) 1.03
Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. Antimicrob Agents Chemother (2003) 1.00
Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol (2001) 0.98
Structural requirements for drug binding to site II on human serum albumin. Mol Pharmacol (1983) 0.98
Plasma concentrations of unbound phenytoin in the management of epilepsy. Br J Clin Pharmacol (1984) 0.96
Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther (1996) 0.94
Protein binding of non-steroidal anti-inflammatory drugs in plasma and synovial fluid of arthritic patients. Br J Clin Pharmacol (1983) 0.93
The effects of N-B transition of human serum albumin on the specific drug-binding sites. Biochim Biophys Acta (1982) 0.92
Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products. Pharm Acta Helv (2000) 0.92
Lidocaine disposition--sex differences and effects of cimetidine. Clin Pharmacol Ther (1984) 0.91
Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats. J Pharm Pharmacol (2001) 0.90
Metabolism of quinine in man: identification of a major metabolite, and effects of smoking and rifampicin pretreatment. J Pharm Pharmacol (1995) 0.90
Fine structural changes in the fibroblasts of canine heart valves prepared for grafting. Thorax (1973) 0.89
Influence of thyroid hormones on the sensitivity of cardiac and smooth muscle to biogenic amines and other drugs. Br J Pharmacol (1970) 0.88
Protein binding of GP53,633: a basic non-steroidal anti-inflammatory drug. Biochem Pharmacol (1982) 0.85
Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. Br J Clin Pharmacol (1995) 0.85
Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population. Pharmacogenetics (1995) 0.84
Interaction of sulphinpyrazone with warfarin. Eur J Clin Pharmacol (1982) 0.84
Effects of cigarette smoking on quinine pharmacokinetics in malaria. Eur J Clin Pharmacol (2002) 0.83
Pharmacokinetics of quinine in young and elderly subjects. Trans R Soc Trop Med Hyg (1992) 0.83
Effects of Chinese, Japanese and Western tea on hepatic P450 enzyme activities in rats. Drug Metabol Drug Interact (2004) 0.83
Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Eur J Clin Pharmacol (1998) 0.83
Cigarette smoking enhances the elimination of quinine. Br J Clin Pharmacol (1993) 0.83
Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin Pharmacol (2000) 0.83
Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol (1983) 0.81
Changes in drug sensitivity in hyperthyroidism. Br J Pharmacol (1969) 0.81
Fine structural changes in rat myocardium induced by daunorubicin. Pathology (1973) 0.80
Pharmacokinetics of quinine in obesity. Trans R Soc Trop Med Hyg (2000) 0.78
A method for evaluating the effects of allograft sterilization procedures on the viability of human fibroblasts. Thorax (1974) 0.77
Kinetics of drug action in disease states. XX. Effects of acute starvation on the pharmacodynamics of phenobarbital, ethanol and pentylenetetrazol in rats and effects of refeeding and diet composition. J Pharmacol Exp Ther (1987) 0.76
Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. Br J Clin Pharmacol (1986) 0.76
Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Metabol Drug Interact (2000) 0.76
Decreased hepatic drug metabolising enzyme activity in rats with nitrosamine-induced tumours. Drug Metabol Drug Interact (2002) 0.76
A clinical trial of a slow-release formulation of acetylsalicylic acid in patients at risk for preeclampsia. Br J Clin Pharmacol (1993) 0.75
Drugs and hyperthyroidism. Br Med J (1968) 0.75
Clinical pharmacology of GP53,633--a new non-steroidal anti-inflammatory drug--in patients with rheumatoid arthritis. Agents Actions (1984) 0.75
The effect of thyroid hormones on the action of some centrally acting drugs. Br J Pharmacol (1970) 0.75
Modeling of subcutaneous absorption kinetics of infusion solutions in the elderly using technetium. J Pharmacokinet Biopharm (1997) 0.75
Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose. J Pharmacokinet Biopharm (1991) 0.75
Oral quinine pharmacokinetics and dietary salt intake. Eur J Clin Pharmacol (2001) 0.75
Observations of conformational changes in human serum albumin following removal of fatty acid by charcoal. J Pharm Biomed Anal (1991) 0.75
In vitro hepatic metabolism of a CYP3A-mediated drug, quinine, in Adélie penguins. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol (1999) 0.75
Use of local anaesthetics in guanethidine-induced regional sympathetic blockade. N Z Med J (1995) 0.75
Effects of cimetidine and ranitidine on halothane metabolism and hepatotoxicity in an animal model. Drug Metab Dispos (1984) 0.75
Novel direct high-performance liquid chromatographic method for determination of salicylate glucuronide conjugates in human urine. J Chromatogr (1991) 0.75
Toxicological evaluation of New Zealand deer velvet powder. Part I: acute and subchronic oral toxicity studies in rats. Food Chem Toxicol (2000) 0.75
Observations on pharmacy practice and advanced pharmacy education in New Zealand. Am J Hosp Pharm (1991) 0.75
Response to beta-blockers in maternal and fetal rat hearts in vitro. Life Sci (1991) 0.75
Adrenoceptor subtypes and their cholinoceptor-induced blockades in mammalian atria. Gen Pharmacol (1979) 0.75